Overview

Update
Total Equity Funding
$28M in 2 Rounds
Most Recent Funding
$14M Series A on May 4, 2015
Headquarters:
San Francisco, CA
Description:
Amphivena Therapeutics, a subsidiary of Affimed Therapeutics, develops treatments to address hematologic malignancies.
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://amphivena.com/
Social:

Company Details

Update

Amphivena Therapeutics Inc., a newly created subsidiary of venture-backed Affimed Therapeutics AG , has raised $14 million in Series A financing and has granted Janssen Biotech an exclusive option to acquire the company.

Affimed has used its TandAb technology to develop a pipeline of treatments for diseases such as Hodgkin lymphoma and non-Hodgkin lymphoma. Its new subsidiary, Amphivena, will use this technology to address hematologic malignancies, but specifics about its drug program and the indications it will pursue haven't been disclosed....

Funding Rounds (2) - $28M

Update
DateAmount / RoundValuationLead InvestorInvestors
May, 2015$14M / Series A0
Jul, 2013$14M / Series A0

Current Team (1)

Update

News (1)

Update

Offices/Locations (1)

Update
  • Office

    45 JUNIPER STREET

    San Francisco, CA 94103

    USA

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos